Top

Published in:

Open Access 01-02-2018 | Hypertension and Obesity (E Reisin, Section Editor)

The Global Epidemic of the Metabolic Syndrome

Author: Mohammad G. Saklayen

Published in: Current Hypertension Reports | Issue 2/2018

Abstract

Metabolic syndrome, variously known also as syndrome X, insulin resistance, etc., is defined by WHO as a pathologic condition characterized by abdominal obesity, insulin resistance, hypertension, and hyperlipidemia. Though there is some variation in the definition by other health care organization, the differences are minor. With the successful conquest of communicable infectious diseases in most of the world, this new non-communicable disease (NCD) has become the major health hazard of modern world. Though it started in the Western world, with the spread of the Western lifestyle across the globe, it has become now a truly global problem. The prevalence of the metabolic syndrome is often more in the urban population of some developing countries than in its Western counterparts. The two basic forces spreading this malady are the increase in consumption of high calorie-low fiber fast food and the decrease in physical activity due to mechanized transportations and sedentary form of leisure time activities. The syndrome feeds into the spread of the diseases like type 2 diabetes, coronary diseases, stroke, and other disabilities. The total cost of the malady including the cost of health care and loss of potential economic activity is in trillions. The present trend is not sustainable unless a magic cure is found (unlikely) or concerted global/governmental/societal efforts are made to change the lifestyle that is promoting it. There are certainly some elements in the causation of the metabolic syndrome that cannot be changed but many are amenable for corrections and curtailments. For example, better urban planning to encourage active lifestyle, subsidizing consumption of whole grains and possible taxing high calorie snacks, restricting media advertisement of unhealthy food, etc. Revitalizing old fashion healthier lifestyle, promoting old-fashioned foods using healthy herbs rather than oil and sugar, and educating people about choosing healthy/wholesome food over junks are among the steps that can be considered.

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5.CrossRefPubMed

National Center for Health Statistics, Division of Health Interview Statistics. Crude and age-adjusted percentage of civilian, noninstitutionalized adults with diagnosed diabetes, United States, 1980–2010. National Center for Chronic Disease Prevention and Health Promotion, Ed. Atlanta, GA, Centers for Disease Control and Prevention, Division of Diabetes Translation, 2012.

Palaniappan LP, Wong EC, Shin JJ, et al. Asian Americans have greater prevalence of metabolic syndrome despite lower body mass index. In J Obe. 2017;35:393–400.CrossRef

Wang Y, Mi J, Shan X, et al. Is China facing an obesity epidemic and the consequences? The trends in obesity and chronic disease in China. Int J Obesity. 2007;31:177–88.CrossRef

2015 Obesity collaborators GBD. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;

Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004), 2008. Arch Int Med. 168:1617–24.

Firmann M, Mayor V, Vidal PM, et al. The CoLaus study: a population based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord. 2008;8:6.CrossRefPubMedPubMedCentral

Ogurtsova K, Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes research and clinicalpractice. 2017;128:40–50. https://doi.org/10.1016/j.diabres.2017.03.024.CrossRef

Delvari A, Forouanafar MH, Alikhani S et al. First nationwide study of the prevalence of the metabolic syndrome and optimal cutoff points of waist circumference in the Middle East.

10.

Yoneshiro T, Aita S, Matsushita M, et al. Recruited brown adipose tissue as an antiobesity agent in humans. J Clin Invest. 2013;123:3404–8.CrossRefPubMedPubMedCentral

11.

Adamczak M, Wiecek A. The adipose tissue as an endocrine organ. Semin Nephrol. 2013;33(1):2–13. https://doi.org/10.1016/j.semnephrol.2012.12.008.CrossRefPubMed

12.

Benrick A, Chanclon B, Micallef P, et al. Adiponectin protects against development of metabolic disturbances in a PCOS mouse model. Proc Natl Acad Sci U S A. 2017:E7187–96.

13.

Jing Y, Wu F, Li D et al. Metformin improves obesity associated inflammation by altering macrophage polarization. Mol cell Endocrinol 2017; epub PMID 28935544.

14.

Shan B, Wang X, Wu Y, Xu C, Xia Z, Dai J, et al. The metabolic ER stress sensor IRE1alpha suppresses alternative activation of macrophages and impairs energy expenditure in obesity. Nat immunolo. 2017;18(5):519–29. https://doi.org/10.1038/ni.3709.CrossRef

15.

Mosialou I, Shikel S, Liu JM, et al. MC4R-dependent suppression of appetite by bone -derived Lipocalin 2. Nature. 2017;543(7645):385–90. https://doi.org/10.1038/nature21697.CrossRefPubMed

16.

Miao Y, Warner M, Gustafsson JK. Liver X receptor beta—a new player in the regulatory network of thyroid hormone and browning of white fat. Adipocyte. 2016;5(2):238–42. https://doi.org/10.1080/21623945.2016.1142634.CrossRefPubMedPubMedCentral

17.

Everard A, Belzer C, Geurts L. Crosstalk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013;110:9066–71.CrossRefPubMedPubMedCentral

18.

Plovier H, Everard A, Druart C, Depommier C, van Hul M, Geurts L, et al. A purified membrane protein from A. muciniphila or pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2017;23(1):107–13. https://doi.org/10.1038/nm.4236.CrossRefPubMed

19.

Kopec AK, Abrahams SR, Thornton S, Palumbo JS, Mullins ES, Divanovic S, et al. Thrombin promotes diet-induced obesity through fibrin-driven inflammation. J Clin Inves. 2017;127(8):3152–66. https://doi.org/10.1172/JCI92744.CrossRef

20.

Villa CR, Chen J, Wen B, Sacco SM, Taibi A, Ward WE, et al. Maternal vitamin D beneficially programs metabolic, gut and bone health of mouse male offspring in an obesogenic environment. In J obes. 2016;40(12):1875–83. https://doi.org/10.1038/ijo.2016.177.CrossRef

21.

• Cox RL. Rationally designed PPARdelta-specific agonists and therapeutic potential for metabolic syndrome. Proc Natl Acad Sci USA. 2017;114:3284–5. While PPAR alpha and PPAR gamma activators are successfully being used in treatment of hyperlipidemia and type 2 diabetes, their use and benefits are limited. The third PPAR receptor PPAR delta is widely expressed in different tissues and activation in animal models improved lipid homeostasis and insulin sensitivity. Wu et al recently developed a highly selective set of chemicals that target PPAR delta paving the way of human use of a PPAR delta agonist to combat metabolic syndrome. CrossRefPubMedPubMedCentral

22.

Stout MB, Justice JN, Nicklas BJ, et al. Physiological aging: links among adipose tissue dysfunction, diabetes and frailty. Physiology. 2017;32(1):9–19. https://doi.org/10.1152/physiol.00012.2016.CrossRefPubMed

23.

Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015;518(7538):197–206. https://doi.org/10.1038/nature14177.CrossRefPubMedPubMedCentral

24.

Ferguson-Smith AC, Patti ME. You are what your dad ate. Cell Metab. 2011;13(2):115–7. https://doi.org/10.1016/j.cmet.2011.01.011.CrossRefPubMed

25.

Heijjmans BT, Tobi EW, Stein AD, et al. Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci U S A. 2008;105(44):17046–9. https://doi.org/10.1073/pnas.0806560105.CrossRef

26.

Bird SR, Hawley JA. Update on the effects of physical activity on insulin sensitivity in humans. BMJ Open Sport Exerc Med. 2017;2:2000143.CrossRef

27.

Hofmann T, Elbelt U, Stengel A. Irisin as a muscle-derived hormone stimulates thermogenesis-a critical update. Peptide. 2014;54:89–100. https://doi.org/10.1016/j.peptides.2014.01.016.CrossRef

28.

Yang Q, Cogswell ME, Flanders WD, Hong Y, Zhang Z, Loustalot F, et al. Trends in cardiovascular health metrics and association with all cause and CVD mortality among US adults. JAMA. 2012;307(12):1273–83. https://doi.org/10.1001/jama.2012.339.CrossRefPubMed

29.

National Diabetes Statistics Report 2017 CDC publication.

30.

Okla M, Kim J, Koehler K, et al. Dietary factors promoting brown and beige fat development and thermogenesis. Adv Nutr. 2017:473–83.

31.

Ono K, et al. Intragastric administration of capsiate, a transient receptor potential channel agonist, triggers thermogenic sympathetic response. J Appl Physiol. 2011;10:789–98.CrossRef

32.

Yoneshiro T, Aita S, Kawai Y, et al. Nonpungent capsaicin analogs (capsinoids) increase energy expenditure through the activation of brown adipose tissue in humans. Am J Clin Nutr. 2012;95:845–50.CrossRefPubMed

33.

• Cheng CW, Villani V, Buono R, et al. Fasting mimicking diet promotes Ngn3-driven beta-cell regeneration to reverse diabetes. Cell. 2017;168:775–88. Low-calorie, low-protein and low-carb but high fat diet fasting mimicking ketogenic diet for 4 days increased the generation of pancreatic beta cells and reversed both T1D and t2D phenotypes in mouse models. CrossRefPubMedPubMedCentral

34.

Liu P, Ji Y, Yuen T, et al. Blocking FSH induces thermogenic adipose tissue and reduces body fat. Nature. 2017;546(7656):107–12. https://doi.org/10.1038/nature22342.CrossRefPubMed

35.

Borgeson E, Johnson AMF, Lee YS, et al. Lipoxin A4 attenuates obesity-induced adipose inflammation and associated liver and kidney disease. Cell Metab. 2015;22:1–13.CrossRef

36.

Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the diabetes prevention program. Ann Intern Med. 2005;142:611–9.CrossRefPubMedPubMedCentral

37.

• Ruderman NB, Carling D, Prentki M, et al. AMPK, insulin resistance and the metabolic syndrome. J Clin Invest. 2013;123:2764–72. Dysregulation of the fuel-sensing enzyme AMP-activated protein kinase (AMPK) is a central pathogenetic factor for insulin resistance and metabolic syndrome. Increasing AMPK either by caloric restriction, exercise or through use of activator drugs like metformin, thiazolidinediones, adipocyte derived hormone adiponectine, GLP1 agonists all improves the insulin resistance/metabolic syndrome. CrossRefPubMedPubMedCentral

38.

Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, et al. Metformin alters the gut microbiome of individual with treatment-naïve type 2 diabetes contributing to the therapeutics effects of the drug. Nat Med. 2017;23(7):850–8. https://doi.org/10.1038/nm.4345.CrossRefPubMed

39.

Zhao Y, Sedighi R, Wang P, Chen H, Zhu Y, Sang S. Carnosic acid as a major bioactive component in rosemary extract ameliorates high-fat diet induced obesity and metabolic syndrome. J Agric Food Chem. 2015;63(19):4843–52. https://doi.org/10.1021/acs.jafc.5b01246.CrossRefPubMed

40.

Jain SG, Puri S,Misra A etal. Effect of oral cinnamon intervention on metabolic profile and body composition of Asian Indians with metabolic syndrome: a randomized double-blind control trial. Lipids Health Dis 2017: 16:113–116, 1, DOI: https://doi.org/10.1186/s12944-017-0504-8.

41.

Lee J, Liu J, Feng X, et al. Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice. Nat Med. 2016;22:1023–36.CrossRefPubMed

42.

Choudhary D, Bhattacharyya S, Joshi K. Body weight management in adults under chronic stress through treatment with Ashwagandha root extract: a double blind randomized, placebo controlled trial. J Evid based complementary altern med. 2017;22:96–106.CrossRefPubMed

43.

Consolim-Colombo FM, Sangaleti CT, Costa FO, et al. Galantamine alleviates inflammation and insulin resistance in patients with metabolic syndrome in a randomized trial. JCI Insight. 2017;20:93340. ( epub ahead of print)CrossRef

44.

Liu J, Lee J, Hernandez MAS, et al. Treatment of obesity with Celastrol. Cell. 2015;161:999–1011. (Celastrol, a pentacyclic triterpene extracted from the roots of Tripterygium wilfordii (Thunder god vine) suppresses food intake increase energy expenditure and leads to ~45% weight loss in hyperleptinemic diet induced obese mice. CrossRefPubMedPubMedCentral

45.

Rosa DD, Grzeskowiak LM, Ferreira CL, et al. Kefir reduces insulin resistance and inflammatory cytokine expression in an animal model of metabolic syndrome. Food Func. 2016;10:3390–4.CrossRef

46.

• Primeau V, Coderre L, Karelis AD, et al. Characterizing the profile of obese patients who are metabolically healthy. Int J obesity. 2011;35:971–81. While obesity is often associated with metabolic syndrome, Obesity is NOT synonymous with MS. These so-called metabolically healthy obese (MHO) are characterized by high levels of insulin sensitivity, absence of hypertension and hyperlipidemia and other features of MS. Epidemiological evidence suggests that MHO may account for as much as 3/5 of the obese population. CrossRef

47.

Cheong KC, Ghazali SM, Hock LK, Subenthiran S, Huey TC, Kuay LK, et al. The discriminative ability of waist circumference, body mass index and waist-to-hip ratio in identifying metabolic syndrome: variations by age, sex and race. Diabetes Metab Syndr. 2015;9(2):74–8. https://doi.org/10.1016/j.dsx.2015.02.006.CrossRefPubMed

48.

• Yamaoka K, Tango T. Effects of lifestyle intervention on metabolic syndrome: a systemic meta-analysis. BMC Med 2012; The relative proportion of patients with resolved MetS was around 2 times greater in the intervention group than the control group. Mean decrease in fasting blood sugar, triglycerides, waist circumference were 11.5 mg/dl, 12.0 mg/dl and 2.7 cm. Systolic and diastolic BP decreased by 6.4 and 3.3 mmHg. There was nonsignificant increase in HDL of 1.3 mg/dl.

49.

Damsgaard CT, Biltoft-Jensen A, Tetens I, et al. Whole-grain intake, reflected by dietary records and biomarkers, is inversely associated with circulating insulin and other cardiometabolic markers in 8-11-year-old children. J Nutr. 2017;147:816–24.CrossRefPubMed

50.

Fletcher JM, Frisvold DE, Tefft N. Non-linear effects of soda taxes on consumption and weight outcomes. Health Econ. 2015;24(5):566–83. https://doi.org/10.1002/hec.3045.CrossRefPubMed

51.

• Bray GA, Nielsen SJ, Popkin BM. Consumption of high fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr. 2004;79:537–43. This influential and frequently cited article created a false belief that the use of high fructose corn syrup (HFCS) causes MetS more than the cane sugar. This created a false sense of security in consuming sweetened food not using HFCS. The assumption was refuted late but it took a decade before the myth was refuted. CrossRefPubMed

52.

• Coleman KJ, Huang YC, Koebrick C, et al. Metabolic syndrome is less likely to resolve in Hispanics and non-Hispanic blacks after bariatric surgery. Ann Surg. 2014;259:279–85. After multivariate adjustment MetS was less likely to resolve in patients with higher BMI, older, male and either Hispanic or non-Hispanic black. CrossRefPubMed

53.

Peeters A, Backholder K. How to influence the obesity landscape using health policies. Int J Obesity. 2017;41(6):835–9. https://doi.org/10.1038/ijo.2017.24.CrossRef

54.

Barres R and Zierath JR. The role of diet and exercise in the transgenerational epigenetic landscape of T2DM. Nature reviews Endocrinology. 2016: 12:441–451. The review discusses the current understanding how life style factors affect the epigenetic landscape in MetS and diabetes.

55.

• Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin psychiatry. While many clinicians noticed the weight gain and increased incidence of diabetes with use of second generation antipsychotic drugs like Clonazapine, Olanzapine, CATIE (Clinical antipsychotic trails of intervention efficacy) and other studies confirmed that use of these drugs are associated with substantial weight gain and associated metabolic disturbances.

56.

Emmerson PJ, Wang F, Du Y, et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat Med. 2017;23(10):1215–9. https://doi.org/10.1038/nm.4393.CrossRefPubMed

57.

• Cimino I, Coll AP, Yeo HS. GDF15 and energy balance: homing in on a mechanism. Nat Med. 2017;23:1119–20. Editorial comments on the 3 recent studies in mice that identified a specific receptor, GFRAL, for the known anorectic peptide GDF15, elaborated on the understanding of its mechanism of action and paved the way for development of novel therapy for obesity and metabolic syndrome. CrossRefPubMed

58.

Salas-salvado J, Bullo M, Estruch R, et al. Prevention of diabetes with Mediterranean diet—a subgroup analysis of a randomized diet. Ann Intern Med. 2014;160:1–10.CrossRefPubMed

Title: The Global Epidemic of the Metabolic Syndrome
Author: Mohammad G. Saklayen
Publication date: 01-02-2018
Publisher: Springer US
Published in: Current Hypertension Reports / Issue 2/2018
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-018-0812-z

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The Global Epidemic of the Metabolic Syndrome

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2018

New Developments in Hypertensive Encephalopathy

Integrative Physiological Aspects of Brain RAS in Hypertension

Hypothalamic Ion Channels in Hypertension

Vasopressin, Central Autonomic Control and Blood Pressure Regulation

Angiotensin-(1–7) and Alamandine on Experimental Models of Hypertension and Atherosclerosis

Pros and Cons of Intensive Systolic Blood Pressure Lowering

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page